-
PerkinElmer To Acquire VisEn Medical, Inc.
8/3/2010
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, recently announced that it has acquired VisEn Medical, Inc., an in vivo molecular imaging technology company based in Bedford, Massachusetts
-
Simulations Plus Launches MedChem Studio
8/3/2010
Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of its MedChem Studio software for drug discovery
-
LifeSci Advisors Initiates Coverage On Keryx Biopharmaceuticals
8/2/2010
LifeSci Advisors, LLC., a leading provider of investment research and investor relations services in the life sciences sector, recently announced that it has initiated coverage on Keryx Biopharmaceuticals, a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease
-
Clinical Researchers At University Of Rhode Island Adopt AB SCIEX Technology To Develop Novel Test To Support Organ Transplants
7/28/2010
AB SCIEX, a global leader in life science analytical technologies, today announced that the Clinical Pharmacokinetics Research Laboratory at the University of Rhode Island's College of Pharmacy is using AB SCIEX mass spectrometry technology to develop a novel test that would enable clinical researchers to use saliva to monitor immunosuppressant drugs commonly administered to make organ transplants successful
-
Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro
7/26/2010
Sequella, Inc., a clinical-stage biopharmaceutical company developing drugs for treatment of life-threatening infectious diseases, announced today the publication of studies in the scientific journal Antimicrobial Agents and Chemotherapy on synergy between SQ109, its lead drug candidate for the treatment of TB, and TMC207, Tibotec lead TB drug candidate.
-
QPS Announces The Acquisition Of Xendo Drug Development
7/26/2010
QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development BV (XDD), headquartered in Groningen, The Netherlands. XDD, a European contract research organization (CRO), will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC.
-
Tibotec Pharmaceuticals Submits New Drug Application For Investigational Once-Daily HIV Treatment TMC278 To U.S. Food And Drug Administration
7/26/2010
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults.
-
Fluxion Biosciences Wins R&D 100 Award For The IonFlux HT System
7/26/2010
Fluxion Biosciences, a leading provider of functional cell analysis systems for drug discovery and diagnostics, today announced that it has won a 2010 R&D 100 Award for its IonFlux™ HT System. The R&D 100 Award places the state-of-the-art IonFlux System in the prestigious company of previous winners such as liquid crystal displays and the anticancer drug Taxol. Known as "the Oscars of Invention", the R&D 100 Award showcases the most significant new technologies commercialized
-
XenoPort Announces Presentation Of Preclinical Data For Acamprosate Prodrug At Fragile X Syndrome Conference
7/23/2010
XenoPort, Inc. (Nasdaq:XNPT) announced today that it has discovered a novel prodrug that has the potential to improve significantly the blood concentration of acamprosate compared with the currently approved formulation of acamprosate. Preclinical data on this new product candidate will be presented tomorrow at the National Fragile X Foundation's 12th International Fragile X Conference in Detroit, Michigan.
-
Selvita Signs A Drug Discovery Services Contract With Rottapharm Madaus
7/21/2010
Rottapharm Madaus and Selvita announced today signature of a services contract for delivery of drug discovery services.
